ethyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate | 1187550-22-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 1187550-22-6
• 化学式: C₁₁H₂₁NO₄
• 分子量: 231.292
• InChiKey: JFAPXRSEKIGSOM-QMMMGPOBSA-N

物化性质

• 沸点：
  311.5±25.0 °C(Predicted)
• 密度：
  1.021±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate 在 盐酸 、 水 作用下， 以 1,4-二氧六环 为溶剂， 生成 L-2-氨基丁酸乙酯盐酸盐
  参考文献：
  名称：

  Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

  摘要：

  The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.04.043
• 作为产物：
  描述：

  乙醇 、 BOC-L-2-氨基丁酸 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
  参考文献：
  名称：

  Cyclic phosphoramidates as prodrugs of 2′-C-methylcytidine

  摘要：

  The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2'-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.04.043

文献信息

• Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels
  申请人：Kyle Donald J.

  公开号：US20130296281A1

  公开（公告）日：2013-11-07

  The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R 1 , and Z 1 -Z 5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及具有式（I）的芳基和杂芳基取代化合物，以及其药学上可接受的盐、前药或溶剂化物，其中G、R1和Z1-Z5如规范中所述。本发明还涉及利用式（I）的化合物治疗对钠通道阻滞有响应的疾病。本发明的化合物特别适用于治疗疼痛。
• Aryl substituted indoles and the use thereof
  申请人：Purdue Pharma L.P.

  公开号：US10202344B2

  公开（公告）日：2019-02-12

  The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

  本发明涉及式（I）的芳基和杂芳基取代的化合物及其药学上可接受的盐、原药或溶液，其中G、R1和Z1-Z5的定义如说明书所述。本发明还涉及使用式（I）化合物治疗对阻断钠通道有反应的疾病。本发明的化合物特别适用于治疗疼痛。
• ARYL SUBSTITUTED INDOLES AND THEIR USE AS BLOCKERS OF SODIUM CHANNELS
  申请人：Purdue Pharma L.P.

  公开号：EP2582666B1

  公开（公告）日：2014-08-13
• ARYL SUBSTITUTED INDOLES AND THE USE THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20160326111A1

  公开（公告）日：2016-11-10

  The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R 1 , and Z 1 -Z 5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
• US9212139B2
  申请人：——

  公开号：US9212139B2

  公开（公告）日：2015-12-15